

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07H 21/04, C12Q 1/68, C12N 15/00, 1/21, A61K 38/19, C07K 14/52, 16/24</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/24758</b> <b>(43) International Publication Date:</b> 4 May 2000 (04.05.00)
<b>(21) International Application Number:</b> PCT/US99/24424 <b>(22) International Filing Date:</b> 18 October 1999 (18.10.99)  <b>(30) Priority Data:</b> 09/178,973 26 October 1998 (26.10.98) US 09/354,243 16 July 1999 (16.07.99) US  <b>(71) Applicant (for all designated States except US):</b> LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DUMOUTIER, Laure [BE/BE]; Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels (BE). LOUHED, Jamila [BE/BE]; Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels (BE). RENAULD, Jean-Christophe [BE/BE]; Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels (BE).  <b>(74) Agent:</b> HANSON, Norman; Fulbright & Jaworski, LLP, 666 Fifth Avenue, New York, NY 10103 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF		
<b>(57) Abstract</b> <p>The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF

5

## FIELD OF THE INVENTION

This invention relates to newly isolated nucleic acid molecules and their uses. The nucleic acid molecules are shown to be upregulated by the cytokine interleukin-9 ("IL-9"). Also disclosed are the proteins encoded thereby. They are described as T Cell Derived Inducible Factors ("TIFs"). These nucleic acid molecules encode proteins which induce STAT activation in cells. They can be used, for example, in the stimulation of regeneration of targeted tissues. Further, their inhibitors or antagonists can be used to retard, prevent or inhibit differentiation of other tissues.

15

## BACKGROUND AND PRIOR ART

The last decade has seen knowledge of the immune system and its regulation expand tremendously. One area of particular interest has been that of research on the proteins and glycoproteins which regulate the immune system. One of the best known families of these molecules are the cytokines. These are molecules which are involved in the "communication" of cells with each other. The individual members of the cytokine family have been found to be involved in a wide variety of pathological conditions, such as cancer and allergies. Whereas sometimes the cytokines are involved in the pathology of the condition, they are also known as being therapeutically useful.

20

25

Interleukins are one type of cytokine. The literature on interleukins is vast. An exemplary, but by no means exhaustive listing of the patents in this area includes U.S. Patent No. 4,778,879 to Mertelsmann et al.; U.S. Patent No. 4,490,289 to Stern; U.S. Patent No. 4,518,584 to Mark et al.; and U.S. Patent No. 4,851,512 to Miyaji et al., all of which involve interleukin-2 or "IL-2." Additional patents have issued which relate to interleukin-1 ("IL-1"),

such as U.S. Patent No. 4,808,611 to Cosman. The disclosure of all of these patents are incorporated by reference herein. More recent patents on different interleukins include U.S. Patent Nos. 5,694,234 (IL-13); 5,650,492 (IL-12); 5,700,664, 5,371,193 and 5,215,895 (IL-11); 5,728,377, 5,710,251, 5,328,989 (IL-10); 5,580,753, 5,587,302, 5,157,112, 5,208,218 (IL-9); 5,194,375, 4,965,195 (IL-7); 5,723,120, 5,178,856 (IL-6), and 5,017,691 (IL-4). Even a cursory review of this patent literature shows the diversity of the properties of the members of the interleukin family. One can assume that the larger cytokine family shows even more diversity. See, e.g., Aggarwal et al., ed., Human Cytokines: Handbook For Basic And Clinical Research (Blackwell Scientific Publications, 1992), Paul, ed., Fundamental Immunology (Raven Press, 1993), pg 763-836, "T-Cell Derived Cytokines And Their Receptors", and "Proinflammatory Cytokines and Immunity." All cited references are incorporated by reference.

The relationships between various cytokines are complex. As will be seen from the references cited herein, as the level of a particular cytokine increases or decreases, this can affect the levels of other molecules produced by a subject, either directly or indirectly. Among the affected molecules are other cytokines.

The lymphokine IL-9, previously referred to as "P40," is a T-cell derived molecule which was originally identified as a factor which sustained permanent antigen independent growth of T4 cell lines. See, e.g., Uyttenhove et al., Proc. Natl. Acad. Sci. 85: 6934 (1988), and Van Snick et al., J. Exp. Med. 169: 363 (1989), the disclosures of which are incorporated by reference, as is that of Simpson et al., Eur. J. Biochem. 183: 715 (1989).

The activity of IL-9 was at first observed on restricted T4 cell lines, failing to show activity on CTLs or freshly isolated T cells. See, e.g., Uyttenhove et al., supra, and Schmitt et al., Eur. J. Immunol. 19: 2167 (1989). This range of activity was expanded when experiments showed that IL-9 and the molecule referred to as T cell growth Factor III ("TCGF III") are identical to MEA (Mast Cell Growth Enhancing Activity), a factor which potentiates the proliferative response of bone marrow derived mast cells to IL-3, as is described by Hültner et al., Eur. J. Immunol. and in U.S. patent application Serial Number 498,182 filed March 23, 1990, the disclosures of both being incorporated by reference herein. It was also found that the human form of IL-9 stimulates proliferation of megakaryoblastic leukemia. See Yang et al., Blood 74: 1880 (1989). Recent work on IL-9 has shown that it also supports

erythroid colony formation (Donahue et al., Blood 75(12): 2271-2275 (6-15-90)); promotes the proliferation of myeloid erythroid burst formation (Williams et al., Blood 76: 306-311 (9-1-90)); and supports clonal maturation of BFU-E's of adult and fetal origin (Holbrook et al., Blood 77(10): 2129-2134 (5-15-91)). Expression of IL-9 has also been implicated in Hodgkins's disease and large cell anaplastic lymphoma (Merz et al., Blood 78(8): 1311-1317 (9-1-90)). Genetic analyses of mice that were susceptible or resistant to the development of bronchial hyperresponsiveness have unraveled a linkage with the IL-9 gene as well as a correlation between IL-9 production and susceptibility in this model (Nicolaidis et al., Proc. Natl. Acad. Sci. USA, 94, 13175-13180, 1997). Human genetic studies also point to the IL-9 and IL-9R genes as candidates for asthma (Doull et al., Am. J. Respir. Crit. Care Med., 153, 1280-1284, 1996; Holroyd et al., Genomics 52, 233-235, 1998). Secondly, IL-9 transgenic mice allowed for the demonstration that increased IL-9 expression result in lung mastocytosis, hypereosinophilia, bronchial hyperresponsiveness and high levels of IgE (Temann et al., J. Exp. Med. 188, 1307-1320, 1998; Godfraind et al., J. Immunol. 160, 3989-3996, 1998; McLane et al., Am. J. Resp. Cell. Mol. 19:713-720 (1999)). Taken together, these observations strongly suggest that IL-9 plays a major role in this disease. Additional work has implicated IL-9 and muteins of this cytokine in asthma and allergies. See, e.g. PCT Application US96/12757 (Levitt, et al), and PCT US97/21992 (Levitt, et al), both of which are incorporated by reference..

IL-9 is known to affect the levels of other molecules in subjects. See Louahed et al., J. Immunol. 154: 5061-5070 (1995; Demoulin et al., Mol. Cell. Biol. 16: 4710-4716 (1996), both incorporated by reference. It will be recognized that the molecules affected have their own functions in biological systems. For example, Demoulin et al. show that many of the known activities of IL-9 are mediated by activation of STAT transcription factors. As such, there is continued interest in trying to identify molecules whose presence and/or level is affected by other molecules, such as cytokines.

The disclosure which follows describes such molecules. It was found that nucleic acid molecules encoding the proteins of the invention were expressed in the presence of IL-9, but not in its absence. Hence, these molecules are, inter alia, "markers" for the expression or effect of IL-9 in a subject. The molecules are referred to as T Cell Derived Inducible Factors

or "TIFs" hereafter. These and other features of the invention will be seen in the disclosure which follows.

### **BRIEF DESCRIPTION OF THE FIGURE**

Figure 1 compares deduced amino acid sequences of murine and human TIF (SEQ ID NOS: 27 and 28, respectively).

### **DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**

#### **Example 1**

The murine lymphoma cell line BW5147 is well known as a cell line which can be grown in vitro, without the need to add any cytokines to its culture medium. In order to identify genes induced by IL-9, samples of BW5147 were cultured either with (200 U/ml), or without IL-9, for 24 hours. Then, total RNA was isolated, using guanidium isothiocyanate lysis, and CsCl gradient centrifugation. These techniques are well known in the art. Following this, polyadenylated RNA was purified from the total RNA, by using an oligo(dT) cellulose column. The isolated, polyA RNA was then used to generate double stranded cDNA. A commercially available oligo(dT) primer was used. Anywhere from 3-5 ug of polyA RNA were heated to 70°C for 10 minutes with 1µg of oligo dT, and then incubated with 5x first strand buffer (250 mM HCl (pH 8.3), 375 mM KCl, 15 mM MgCl<sub>2</sub>), 10 mM dithiothreitol, 500 uM of deoxynucleotide triphosphates, and 800 U of reverse transcriptase. Total volume of the reaction mixture was 20 ul, and the reaction was allowed to proceed at 37°C for one hour. This resulted in synthesis of the first stand of cDNA. Second strand synthesis was accomplished by adding 30ul of 5 second strand buffer (100mM Tris-HCl (pH 6.9)), 450mM KCl, 23mM MgCl<sub>2</sub>, 0.75mM β-NAD<sup>+</sup>, 50mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, together with 60U of E. coli derived DNA polymerase I, 2U of E. coli RNase H, 10 U of E. coli DNA ligase, and 250 uM of deoxynucleotide triphosphates, and brought to a final volume of 150 ul. The mixture was incubated for two hours, at 16°C.

The product was extracted using phenol-chloroform, and was precipitated with ethanol. The final cDNA product was then resuspended in 200 µl of TE.

These steps were carried out for both the stimulated BW5147 cells ("tester" hereafter), and for parallel, unstimulated BW5147 cells ("driver" hereafter).



Example 2

The cDNA prepared in Example 1 was then subjected to subtraction cloning in accordance with well known methods. To do this, six oligonucleotides were prepared:

5'-AGCACTCTCC AGCCTCTCAC CGCA-3 (SEQ ID NO: 1);

5 5'-GATCTGCGGT GA-3' (SEQ ID NO: 2);

5'-ACCGACGTCG ACTATCCATG AACA-3' (SEQ ID NO: 3);

5'-GATCTGTTCA TG-3' (SEQ ID NO: 4);

5'-AGGCAACTGT GCTATCCGAG GGAA-3' (SEQ ID NO: 5); and

10 5'-GATCTTCCCT CG-3' (SEQ ID NO: 6).

These were used as explained herein. Double stranded cDNA (2 ug), was digested with restriction endonuclease DpnII, extracted with phenol-chloroform, precipitated with ethanol, and resuspended in 20 ul of TE (10mM Tris-HCl (pH 7.5); 1mM EDTA). Twelve ul (1.2  
15 ug), of cut cDNA was ligated to double stranded SEQ ID NOS: 1 and 2, in a mixture which included 4 ul of desalted SEQ ID NO: 1 (2mg/ml), 4 ul desalted SEQ ID NO: 2 (1 mg/ml), 10µl of 5X adapter buffer (330mM Tris-HCl, pH 7.6, 50mM MgCl<sub>2</sub>, 5mM ATP), 7µl DTT (100mM), and 28µl of H<sub>2</sub>O). The oligonucleotides were annealed to each other and to the sample DNA by heating the mixture to 50°C and then cooling it to 10°C over one hour,  
20 followed by adding 5ul of T4 DNA ligase, and incubation for 12-14 hours, at 12-16°C. The mixtures were diluted by adding 140 ul of TE. PCR was then carried out on 200 ul samples, as described infra.

Example 3

To carry out PCR, 200 ul samples containing 2 ul of the ligation product in a buffer  
25 of 66 mM Tris-HCl, pH 8.8, 4 mM MgCl<sub>2</sub>, 16 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 33 ug/ml BSA, 0.3 mM of each dNTP (concentration: 500 µM), and 2 ug of SEQ ID NO: 2 were first heated at 72°C

for three minutes to remove any of SEQ ID NO: 1 which was hybridized to the product of Example 2. The 3' ends were then filled in by using 5U of Taq polymerase (5 minutes, 72°C). Twenty cycles of amplification were carried out (1 cycle: 1 minute at 95°C, and three minutes at 72°C), after which products were combined, phenol extracted, ethanol precipitated, and resuspended in TE buffer, at a concentration of 0.5 ug/ul. Hereinafter, this is referred to as the representation.

#### Example 4

The representation was then prepared for subtractive hybridization by removing SEQ ID NO: 1 therefrom by digestion with Dpn II. The resulting digest was phenol extracted and ethanol precipitated. In the case of the unstimulated sample, this resulted in the driver, while the stimulated sample resulted in the tester. Portions of tester (20 ug) were gel purified on a 1.2% agarose gel and isolated. Samples (2 ug), were ligated to SEQ ID NOS: 3 and 4, in the same way that SEQ ID NOS: 1 and 2 were ligated, as described, supra.

In a first cycle of subtractive hybridization, 0.4 ug samples of tester with SEQ ID NOS: 3 and 4 ligated thereto were mixed with 40 ug of driver cDNA. The mixture was phenol extracted, ethanol precipitated, dissolved in 2 ul of 3XEE buffer (30mM EPPS pH 8.0), 3mM EDTA; pH 8.0, 3 mM EDTA. This was overlaid with 30 ul of mineral oil, and denatured for five minutes at 98°C. A 5M NaCl solution (0.5 ul) was added, and DNA was hybridized for 20 hours, at 67°C. The reaction mixture was diluted to 200 ul with TE, and tRNA carrier. The samples were incubated for three minutes at 72°C to melt away SEQ ID NO: 4, and then four PCR reactions (200 ul) were prepared. These included 20 ul of diluted hybridization mix without primer, to fill in the ends of the reannealed tester, followed by 10 cycles of amplification after adding samples of SEQ ID NO: 3 (1 cycle: 1 minute at 95°C, three minutes at 70°C) after which products were combined, phenol extracted, ethanol precipitated, and resuspended in 40  $\mu$ l of 0.2XTE buffer. Single stranded DNA was degraded by a 30 minute treatment of 20  $\mu$ l of this material with 20U of mung bean nuclease, at a total volume of 40 ul. Samples was diluted (1:5), in 50 mM Tris-HCl, at pH 8.9, followed by five minutes of heating at 98°C to inactivate the enzyme. A second PCR was carried out, using 20 ul of the product described supra, 2 ul of SEQ ID NO: 3 (1 mg/ml), and 1 ul (5 U) of Taq DNA polymerase. A total of 18 cycles (1 cycle: 1 minute at 95 °C, three minutes at 70°C) were



carried out. Products were combined, phenol extracted, ethanol precipitated, and resuspended at 0.5-1 ug/ $\mu$ l. The product is referred to hereafter as "DP1", or the first difference product.

#### Example 5

DP1 was then digested with endonuclease DpnII, as described above, and was ligated to SEQ ID NOS: 5 and 6, following the same processes described for SEQ ID NOS: 1, 2, 3 and 4. Subtractive hybridization and selective amplification, as described in example 4, was repeated, and second difference product, or "DP2", was generated. In these experiments, 50 ng of DP1 was the tester. The driver (40 ug), was as described supra. The process was repeated to generate a third difference product, using SEQ ID NOS: 3 and 4 as adapters. To generate the third product, 100 pg of tester were mixed with 40  $\mu$ g of driver. All steps of the protocols supra were repeated, except the final amplification was carried out for 22 cycles, where one cycle was one minute at 95°C, and three minutes at 70°C. This yielded the final difference product.

#### Example 6

The final difference products were digested with DpnII, and then cloned into the BamHI site of a commercially available vector, i.e., pTZ19R. Double stranded DNA plasmids were prepared, and then sequenced, using standard methods. The sequences were compared to known sequences in the GenBank and EMBL data bases, using a BLAST search program.

At the end of this subtraction procedure, a short cDNA fragment was identified, i.e., a fragment about 200 base pairs long. This fragment was used to screen a cDNA library from BW 5147 cells. The largest clone was sequenced. It is discussed infra. It does not correspond to any known sequence.

The nucleotide sequence (SEQ ID NO: 7), is 1121 bases long, including a 537 base pair open reading frame, which encodes a protein 179 amino acids long. The predicted molecular weight of the protein is 20,093. There are two additional ATG codons which, if they acted as start codons, would produce proteins 172 and 167 amino acids in length, with molecular weights of 19,335 and 18,770 daltons, respectively. Each form of the protein is characterized by a sequence of hydrophobic amino acids which would be cleaved off of the molecule via the endoplasmic reticulum to provide a mature protein.

Analysis of the sequence shows three AT rich motifs (TTATTTAT). These motifs are often found in 5' - untranslated regions of cytokines and oncogenes. Kruys, et al., Science 245: 852 (1989), have shown that these repeats modulate stability of mRNA for TIF.

#### Example 7

5       The cDNA isolated and analyzed in example 6, supra, was then used as a probe to identify genomic DNA for TIF $\alpha$ .

10       A genomic library prepared from mouse strain 129 was screened with SEQ ID NO: 7, following standard methods. An EcoRI fragment from a positive clone was subcloned into plasmid pZERO and partially sequenced. The partial sequence is presented as SEQ ID NO: 8:

#### Example 8

15       A second EcoRI fragment from the positive clone described in Example 7, supra, was also subcloned. There was a great deal of homology, but the sequences were not identical. To be specific, intron 1 of this sequence was 98% identical to SEQ ID NO: 8, intron 2 was 100% identical and intron 3 was 92% identical.

20       What is striking about the sequences is that the promoters are not at all homologous, suggesting independent regulation. The 5' untranslated regions are 92% identical. The first exon for TIF $\alpha$  is split into exon 1 $\alpha$  and exon 1 $\beta$ . The first coding exon (which is exon 1b for TIF $\alpha$  and exon 1 for TIF $\beta$ ) are 99.5% identical, while the second exons are 100% identical, the third exons 97% identical, the fourth exons 98.5% identical, and 96% for the fifth exon. In the untranslated 3' - region, homology is 96%.

#### Example 9

25       Using the information described in example 8, supra, a cDNA sequence for the second clone, designated TIF $\beta$  was deduced, and is set forth as SEQ ID NO: 9. The genomic DNA sequence was also ascertained, in the same manner as is described, supra, and is set forth as SEQ ID NO: 29.

As compared to the coding region for TIF $\alpha$ , that of TIF $\beta$  has six silent changes. There are two changes which result in an inconsequential amino acid change (at both of positions 36

and 113, Val in TIF $\alpha$  becomes Ile in TIF $\beta$ ). There is also a more significant change, at position 112, where Gln becomes Arg.

#### Example 10

Experiments were undertaken to study expression of the TIFs. BW 5147 cells were stimulated with recombinant murine IL-9 (200U/ml), for varying periods of time (0.2, 0.5, 1, 2 & 24 hours). Total RNA was then isolated, using standard methods and reagents. Reverse transcription was then carried out, using 5 $\mu$ g total RNA and an oligo (dT) primer. Samples of cDNA corresponding to 20ng of total RNA were then amplified for 25 cycles using different primers. (One cycle was 4 minutes at 94 °C, 1 minute at 57°C, and 2 minutes at 72°C). The TIF primers were:

5'-CTGCCTGCTT CTCATTGCCC T-3' (SEQ ID NO: 10)

and

5-CAAGTCTACC TCTGGTCTCA T-3' (SEQ ID NO: 11)

(sense and antisense, respectively).

These correspond to nucleotides 106-126, and 764-784 of SEQ ID NO: 7, respectively. As a control,  $\beta$ -actin was amplified as well, for 18 cycles (first cycle: 4 minutes at 94°C, 1 minute at 60°C, 2 minutes at 72°C. Succeeding cycles were 1 minute at 94°C, 1 minute at 60°C, 2 minutes at 72°C).

Following amplification, post PCR products were analyzed on a 1 % agarose gel, and specific amplification was confirmed, following blotting, using internal radioactive probes. The probe for TIF was:

5'-GACGCAAGCA TTTCTCAGAG-3' (SEQ ID NO: 12)

the conditions and probes set forth were not specific for one or the other of the forms of TIF; however, the amplification product of TIF $\alpha$  contains a KpnI restriction site, while the restriction site for TIF $\beta$  does not. Digestion of the amplification products with KpnI indicated that most, if not all, of the TIF mRNA induced by IL-9 was TIF $\alpha$ , suggesting that the TIF $\alpha$  expression was induced rapidly via the IL-9. The mRNA for TIF $\alpha$  was detectable after 30 minutes of stimulation, and reached a plateau over a 1-24 hour time period.

#### Example 11

Experiments were then carried out which showed that the induction of TIF mRNA by IL-9, described supra, does not require protein synthesis. In these experiments, total RNA was extracted from cells stimulated for 24 hours, as described in example 10, but with or without 10 $\mu$ g/ml of a protein synthesis inhibitor, cycloheximide, for 4.5 hours. In a parallel set of experiments, cells were not stimulated. The total RNA was extracted, and RT-PCR amplification was carried out as described in example 10. Post-PCR products were analyzed on an ethidium bromide-stained, 1% agarose gel. What was seen was that the induction by IL-9 still occurred when protein synthesis was blocked. Hence, the effect of IL-9 is a direct effect, not requiring the synthesis of a protein mediator.

#### Example 12

In these experiments, the role of STAT proteins in induction of TIF mRNA was studied on derivatives of the cell line BW5147. The first line, BWh9R, expresses wild type human IL-9 receptors. The line BW-Phe116 is a transfectant with a single mutation (at position 116), which renders the receptor unable to activate STAT transcription factors. Still another cell line, BW-mut6, has a mutation which renders the receptor unable to activate STAT5, while retaining the ability to activate STAT1 and STAT3. Finally, cell line BW-mut7 has a single mutation which renders the IL-9 receptor unable to activate STAT1 and STAT3, but which retains the ability to activate STAT5.

Cell stimulation, isolation of total RNA, reverse transcription and amplification of cDNA were all carried out as described in example 10 (Cells were stimulated for 24 hours. Both human and murine recombinant IL-9 were used). The PCR products were analyzed on an ethidium bromide stained, 1% agarose gel, as describe supra.

The analysis revealed that human IL-9 did not induce expression in BW-Phe116, suggesting that STAT transcription factors are implicated. It was found that IL-9 induced TIF expression in the BW-mut6 mutant, but not the mut7 variant, suggesting that STAT1 or STAT3 are involved, but not STAT5.

#### Example 13

The expression of TIF mRNA in normal mouse spleen cells was then studied.

Spleen cells from 10-12 week old Balb/c mice were cultured for 24 hours in control medium or the control medium supplemented with 20 $\mu$ g/ml of LPS (which activates B

lymphocytes and macrophages), or ConA (which activates T cells), or ConA plus 1% of a blocking antiserum against murine IL-9, with  $\beta$  actin being used as a control. Purification of RNA, RT-PCR analysis were carried out as described supra.

5 The data indicated that TIF is, at best, very weakly expressed in resting spleen cells, not induced by LPS, but strongly induced by ConA. Anti IL-9 antiserum did not affect induction by ConA, suggesting that its effect is not mediated by IL-9, or is mediated by other cytokines.

When the ConA activated spleen cells were analyzed using sequences of RT-PCR products, it was found that these cells were expressing TIF $\alpha$  predominantly, or exclusively.

#### 10 Example 14

Further experiments showed that TIF mRNA was expressed even in the absence of IL-9 induction.

Spleen cells from 5 week old FVB mice were enriched for T cells, using a nylon wool column. Then, the cells were stimulated for 24 hours in medium supplemented with ConA  
15 (a T cell activator), or PMA (which activates PKC in most cells), either with or without IL-9.

Total RNA was isolated using standard techniques, and then ten microgram samples were fractionated via electrophoresis on a 1.3% agarose gel containing 2.2M formaldehyde. The fractions were then transferred to a nitrocellulose membrane, labeled, and assayed in a hybridization assay following Van Snick, et al, J. Exp. Med. 169: 363 (1989), incorporated  
20 by reference.

The results indicated that the induction of TIF by ConA was not modified, and that IL-9 did not induce TIF RNA in PMA activated spleen cells.

#### Example 15

The expression of TIF mRNA in various cell lines was tested. In these experiments,  
25 murine cell lines were stimulated for at least one day, with a particular cytokine. Specifically, 9T7 is a T cell lymphoma, which responds to IL-2, IL-4 or IL-9. Cell lines TS3 and TS6 are derived from T helper cell clones, and proliferate in the presence of either IL-2 or IL-9. MC9 and LI38 are mast cell lines, which proliferate in the presence of either IL-3 or IL-9.

Following stimulation, total RNA was prepared using standard guanidium isothiocyanate lyses, and CsCl gradient centrifugation.

The 9T7 line was then analyzed by Northern blotting, as described in example 14, while the other lines were assayed using RT-PCR analysis, as described supra.

5        It was found that IL-9 upregulated TIF expression in T helper cells and mast cells, while IL-2 and IL-3 did not. The 9T7 cell line, however, showed roughly the same level of expression, regardless of the cytokine, indicating that IL-9 is not mandatory for TIF expression.

#### Example 16

10        The expression of TIF mRNA in B cell lines was then studied. The cell lines A20, 70Z/3, and BCL-1 are B cell leukemia cell lines which grow, in vitro, without cytokines. These cells were stimulated for 24 hours with IL-4 and IL-9 and total RNA was isolated, using standard methods. Expression was analyzed by RT-PCR which was carried out for 35 cycles, followed by blotting and hybridization, as described supra.

15        The results indicated that TIF expression is detectable in B cells, but is weakly upregulated at best in the presence of IL-9 and IL-4.

#### Example 17

20        Experiments were then carried out to study expression of the inventive molecules in T helper cell lines. TS2 and TS1 are known T helper cell lines, derived from T helper cell clones, which proliferate in the presence of either IL-9 or IL-2 (TS2), and either IL-9 or IL-4 (TS1). Specifically, TS1 or TS2 cells were grown in the presence of the listed cytokines for at least 10 days, after which RNA was extracted using known methods. Expression of the molecules was studied via RT-PCR (35 cycles), using the protocols described supra. In TS1 cells both IL-4 and IL-9 induce TIF expression, but IL-2 does not do so in TS2 cells.

#### 25        Example 18

Expression of TIF mRNA in various mouse organs were studied. Total RNA was prepared from liver, kidney, heart, brain, intestine, spleen, thymus, lung, muscle and bone marrow, using standard guanidium isothiocyanate methodologies and CsCl gradient



centrifugation. Forty cycles of RT-PCR were carried out, using the protocols described supra. Strongest expression was found in thymus tissue, while less intense signals were found in brain tissue, and weaker expression in the remaining tissues.

#### Example 19

5 The following experiments describe production of TIF $\alpha$  in 293-EBNA cells.

Complementary DNA for TIF $\alpha$  was described supra. It was subcloned into a commercially available expression vector pCEP-4, in operable linkage with a CMV promoter. The resulting plasmids were transfected into 293-EBNA cells, using standard lipofectamine methods. Following transfection, the cells were incubated in a methionine free medium,  
10 supplemented with  $^{35}\text{S}$  labeled methionine, for 24 hours. Supernatant was harvested, and run on an acrylamide gel, followed by electrophoresis. The gel was then dried and exposed to autoradiography for 1 day. A control was then run by transfecting cells with the same plasmid, in which the cDNA was cloned in the antisense direction.

A heterogenous band of about 25–30 kilodaltons was found from the cells transfected  
15 with TIF in the sense direction. Any discrepancies between the predicted molecular weight, the actual molecular weight in the system, and the heterogeneity, can be attributed to glycosylation. In a series of parallel experiments, cDNA encoding human TIF was expressed in the same way as the murine cDNA was expressed. With the exception of the change of the cDNA, all experimental parameters were the same.

#### Example 20

20 Further experiments were carried out to study production of TIF $\alpha$  in COS cells. Specifically, TIF $\alpha$  cDNA was subcloned into the plasmid pEF-BOS.puro described by Demoulin et al., supra, in operable linkage with the EF-1 $\alpha$  promoter. The plasmid cDNA was transfected into COS cells, using the same lipofectamine method described supra. The cells  
25 were incubated in methionine free medium, supplemented with  $^{35}\text{S}$  methionine for 24 hours, after which supernatant was treated as described in example 20, supra. Again, a heterogenous band of 25–30 kilodaltons was observed, as well as an 18 kilodalton band, which probably represents a non-glycosylated form of the molecule.

Example 21

In these experiments, it was discovered that TIF induces STAT activation in mesangial, neuronal melanoma, and hepatoma cells. It is known that when cytokines activate STAT factors, the factors dimerize, move from cytoplasm to the nucleus, and bind to target sequences in promoters. The details of the experiments follow.

Transfected 293-EBNA cells as described supra were used following incubation in normal medium for 48 hours, as were supernatant from the controls, also described supra. Samples of a mouse kidney mesangial cell line, ("MES13" hereafter), a rat pheochromocytoma cell line, ("PC12" hereafter), four different human melanomas (SK23, AUMA, NA-8mel and MULL), human hepatoma (HepG3) and rat hepatoma (H-4-II-K) were used. Cell samples ( $0.5 \times 10^6$ ) were stimulated for 5-10 minutes in the presence of 1% of supernatant. Nuclear extracts were then prepared, in accordance with Demoulin et al., Mol. Cell. Biol. 16: 4710 (1996), incorporated by reference. In brief, cells were washed with PBS and then resuspended in 1 ml of ice cold hypotonic buffer for 15 minutes. (Buffer was 10mM HEPES buffer, pH 7.5, with 10mM KCl, 1mM  $MgCl_2$ , 5% glycerol, 0.5 mM EDTA, 0.1mM EGTA, 0.5mM dithiothreitol, and 1mM Pefabloc, 1mM  $Na_3V_4$ , and 5mM NaF). Cells were then lysed by adding 65  $\mu$ l of NP-40, followed by vortexing. Nuclei were pelleted, by vortexing for 30 seconds at 14,000 rpm, followed by extraction in buffer supplemented with HEPES (20mM), glycerol (20%), and NaCl (420mM). Nuclear debris was removed by centrifuging for 2 minutes. DNA binding activity was determined in accordance with Demoulin et al., supra, using a  $^{32}P$  labeled double stranded oligonucleotide called "GRR," which contains the STAT binding site of the Fc $\gamma$ RI gene promoter, i.e.:

5'ATGTATTTC CAGAAA-3' (SEQ ID NO: 13)

and

5'-CCTTTTCTGG GAAATAC-3' (SEQ ID NO: 14)

corresponding to the upper and lower strands of the binding sites in the GRR probe. Briefly, 5 $\mu$ l volume of nuclear extracts were incubated in binding buffer (12mM HEPES, pH 7.6, 10mM KCl, 0.5mM EDTA, 2.5% glycerol, 0.1mg of poly(dI-dC) per ml) for 5 minutes. Radiolabeled GRR probe ( $10^5$ cpm; approximately 0.5ng) was added, and incubation was continued for 25 minutes before loading onto a non-denaturing polyacrylamide gel.

It was also noted that the complexes observed in MES13 cells, described supra, were partially overshifted by both anti-STAT5 and anti-STAT3 antibodies, showing that (i) the cells under examination were targets for TIF, and (ii) that STAT3 and STAT5 are major components of the complex activated by TIF. The difference in STAT profile, as compared to the profile in Example 12, supra, is attributable to the difference in cell source (human versus mouse). It was also observed that human TIF works on murine cells, and vice versa.

#### Example 22

This example details the isolation and cloning of a nucleic acid molecule which encodes human TIF. First, human peripheral blood mononuclear cells were prepared via standard density gradient centrifugation. Following this preparation, samples were cultured for 24 hours, at  $3 \times 10^6$  cells/ml, either with or without anti-CD3 monoclonal antibody (The antibody was the commercially available OKT3 mAb, used in the form of ascites fluid at 1/500 dilution). This antibody was used because T cell derived cytokines are generally expressed only upon activation by e.g., CD3 specific antibodies.

Total RNA was isolated from these cells, using standard guanidine-isothiocyanate / CsCl ultra-centrifugation techniques. Following isolation,  $10\mu\text{g}$  samples of the RNA were reverse transcribed using an oligo (dT)15 primer.

Following preparation of cDNA, as outlined supra, samples which corresponded to 100ng of total RNA were amplified, via PCR, using the following primers:

5' - AGCTGCTCAA CTTCAACCCTG GA - 3' (SEQ ID NO: 15)

5' - CCACTCTCTC CAAGCTTTTT CA - 3' (SEQ ID NO: 16)

which are based upon a murine cDNA sequence, (i.e., SEQ ID NO: 7). The PCR conditions involved 30 cycles of amplification, with one cycle defined as 1 minute at  $94^\circ\text{C}$ , followed by 1 minute at  $42^\circ\text{C}$ , and then 2 minutes at  $72^\circ\text{C}$ . Amplification product was separated on an agarose gel, using standard methods, and then sequenced. The result indicated that fragments of the cDNA had been amplified. Hence, a second reaction was carried out, using the same materials except SEQ ID NO: 16 was replaced by SEQ ID NO: 17, i.e.:

5' - CAAGTCTACC TCTGGTCTCA T - 3'

This second PCR reaction was carried out for 25 cycles, with one cycle being defined as 1 minute at  $94^\circ\text{C}$ , followed by 1 minute at  $45^\circ\text{C}$ , and then 2 minutes at  $72^\circ\text{C}$ . The

amplification product was subjected to the same steps as the first one. Again, fragments of cDNA were amplified.

### Example 23

Following preparation of amplification product, the 5' end of cDNA was isolated by using standard, 5' - RACE techniques. In brief, first strand cDNA was prepared by using SEQ ID NO: 18 as a primer, i.e.:

5' - TGGCCAGGAA GGGCACCACC T - 3'

This primer was based upon the sequence information obtained in accordance with example 22. In brief, the 5' - RACE method was carried out by combining 1  $\mu$ g of total RNA, prepared as described *supra*, 2.5 pmoles of SEQ ID NO: 18, reverse transcriptase, reverse transcriptase buffer, 2.5  $\mu$ l of dNTP mix (10 mM), 2.5  $\mu$ l of  $MgCl_2$  (25mM), and 2.5  $\mu$ l of dithiothreitol (0.1 M). The reaction was carried out and, after completion, original RNA was removed via adding RnaseH, and Rnase TI. Any unincorporated dNTPs, as well as primer and proteins, were removed. The cDNA was tailed using terminal transferase, or "TdT." This enzyme creates a 3'-binding site for the abridged anchor primer, as described *infra*. Tailing was carried out by combining the purified, first strand cDNA, TdT, buffer (10 mM Tris-HCl, 25 mM KCl, 1.5 mM  $MgCl_2$ ), and 200  $\mu$ M of dCTP.

Following the tailing reaction, PCR was carried out using

5' - TGGCCAGGAA GGGCACCACC T - 3' (SEQ ID NO: 19),

and 5' - RACE abridged anchor primer:

5' - GGCCACGCGT CGACTAGTAC GGGIIGGGIIGGGIIG - 3' (SEQ ID NO: 20).

The amplification involved 35 cycles (1 cycle defined as 1 minute at 94°C, 1 minute at 56°C, and 2 minutes at 72°C). Following this, nested amplification was performed on 5  $\mu$ l of a 1/100 dilution of the amplification product, using SEQ ID NO: 19 and the abridged universal amplification primer:

5' - GGCCACGCGT CGACTAGTAC - 3' (SEQ ID NO: 21).

Amplification involved 30 cycles (1 cycle being defined as 1 minute at 94°C, 1 minute at 56°C, and 2 minutes at 72°C). The resulting PCR product was cloned, following standard procedures, and sequenced.

These three protocols, i.e., the two experiments described supra which generated fragments, and the 5' - RACE PCR, also described supra, permitted alignment of the sequenced amplification product, to generate the complete sequence.

Following the alignment, oligonucleotides were generated which flanked the deduced open reading frame, i.e.:

5' - CCTTCCCCAG TCACCAGTTG - 3' (SEQ ID NO: 22)

and

5' - TAATTGTTAT TCTTAGCAGG - 3' (SEQ ID NO: 23).

These primers were used to amplify the entire open reading frame, using mRNA from CD3 specific mAb stimulated cells, as described supra. For amplification, 25 cycles (1 cycle being defined as 1 minute at 94°C, 1 minute at 56°C, and 2 minutes at 72°C).

The complete sequence of the human cDNA is set forth at SEQ ID NO: 24.

As with the murine sequence, there are potential start codons at positions of SEQ ID NO: 24 which correspond to amino acids 1 and 13, as well as codons corresponding to methionine at amino acid positions 58, 85, and 92. The possible initiator codons correspond to proteins with calculated molecular weight of 19,998 daltons, and 18,735 daltons respectively (for 176 or 167 amino acids, respectively). As with the murine form of the protein, hydrophobic leader sequences are seen, indicating an N-terminal signal sequence of from about 20 to about 40 amino acids.

#### Example 24

These experiments detail work on the isolation of human genomic DNA corresponding to the cDNA discussed supra.

Based upon the cDNA sequences, primers were developed which correspond to nucleotides 51-70 and the complement of nucleotides 631-650 of SEQ ID NO: 24. PCR was carried out, using standard methodologies. Specifically, 100ng of genomic DNA was used as a template, and 33 cycles of amplification were carried out (one cycle of amplification being defined as 94° C for 30 seconds, 50° C for 30 seconds, and 72° C for 5 minutes). Once a sequence was isolated, it was sequenced, and this is set forth as SEQ ID NO: 25. The sequence is about 4.8 kilobases in length, and is believed to contain the entire genomic



sequence encoding the TIF molecule, lacking only the 5' flanking region, the promoter, and the 3' end.

#### Example 25

It was of interest to identify where the genomic DNA discussed supra was located in the human genome. In order to do this, two different approaches were taken. In the first, the sequence discussed supra, i.e., SEQ ID NO: 25, was labeled with a fluorescent label, and then was used to probe the human genome via fluorescent, in situ hybridization ("FISH") using standard methods.

In a second approach, a panel of radioactive hybrid clones were screened using the probe consisting of nucleotides 51-70 of SEQ ID NO: 24, and 5'-ATCAGATGGA TTACTGAATG-3' (SEQ ID NO:26). PCR was carried out using 25 ng of genomic DNA as a template, for 35 cycles, where one cycle is defined as 94 °C for 1 minute, 55° C for 1 minute and 72 °C for 2 minutes.

Both methodologies indicated that the gene is located at chromosome 12q15. Some work links diseases associated with asthma at this site. See, e.g. Nat. Genet. 15:389-392 (1997); Ober, et al, Hum. Mol Genet. 7(9):1393-1398(1998); Nickel, et al, Genomic 46(1):159-162(1997); Takahashi, et al, Genomics 44(1):150-2(1997); Barnes, et al, Genomics 37(1):41-50(1996), all incorporated by reference..

#### Example 26

These experiments describe the manufacture of antibodies which bind to the TIF protein. To make these, a peptide consisting of amino acids 40-61 encoded by SEQ ID NO: 7 was coupled to KLH carrier protein, using standard methods and a ratio of 1 mg peptide to 1 mg carrier protein. Subject animals (rabbits), were immunized 3 times, at 2 week intervals, with 150 µg of the complex. The immunogen was emulsified in Complete Freund's Adjuvant for the first injection, and then Incomplete Freund's Adjuvant for the next two.

A first bleed was performed one month after the last injection, and serum was prepared, following known methods.

The serum was then tested in a standard Western Blot. In brief, 10 µl of supernatant from cells transfected with either SEQ ID NO: 7 or SEQ ID NO:24 were separated via SDS-



PAGE electrophoresis, and then blotted onto PVDF membranes. Antiserum was diluted to 1:500, and used in a standard Western Blot protocol, together with anti-rabbit antibody as the secondary antibody, and a commercially available detection kit.

It was found that the serum did, in fact, recognize the TIF protein.

5 In figure 1, the deduced amino acid sequences of murine and human TIF are set out. The high degree of homology is seen in the boxed regions.

The foregoing examples describe the invention, one aspect of which are isolated nucleic acid molecules, which encode TIF proteins such as those with the amino acid sequence of the protein encoded by the nucleotide sequence of SEQ ID NO: 7, 24 or 25. It will be appreciated by one of ordinary skill that the degeneracy of the genetic code facilitates the preparation of nucleic acid molecules which may not be identical to the nucleotide sequence of SEQ ID NO: 7, 24 or 25, but which encode the same protein. Of course, SEQ ID NOS: 7, 24 and 25 are preferred embodiments of this invention, but other embodiments are also a part of the invention. Genomic DNA, complementary DNA, and RNA, such as messenger RNA, are all to be included therein. Isolated nucleic acid molecules from other animal species, including other mammals, are also a part of the invention. A preferred aspect of the invention are isolated nucleic acid molecules whose complements hybridize to SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 24 under stringent conditions. "Stringent conditions," as used herein, refer, for example, to hybridization at 65°C in buffer (3.5xSSC), 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 25mM NaH<sub>2</sub>PO<sub>4</sub> (pH 7), 0.1% SDS, 2mM EDTA, followed by a final wash at 2xSSC, room temperature and then 0.1xSSC/0.2xSDS at temperatures as high as, e.g., about 65°C. More stringent conditions, such as 0.1xSSC, can also be used. These nucleic acid molecules encode proteins of about 17-22 kD as determined by SDS - PAGE, which activates STAT proteins, such as STAT 1, STAT3 and/or STAT5. In glycosylated form, these proteins can range from about 17 to about 30 kilodaltons, as determined by SDS - PAGE.

Also a part of the invention are expression vectors which include the nucleic acid molecules of the invention, operably linked to a promoter, so as to facilitate expression of the DNA. It is well within the skill of the artisan to prepare such vectors.

30 The vectors, as well as the nucleic acid molecules per se, can be used to prepare recombinant cells, be these eukaryotic or prokaryotic, wherein either an expression vector or

the nucleic acid molecule itself is incorporated therein. E. coli cells, COS cells, CHO cells, etc., are all examples of types of cells which may be used in accordance with this aspect of the invention.

Proteins encoded by the above referenced nucleic acid molecules, preferably in isolated form, are another feature of this invention. By "protein" is meant both the immediate product of expression of the nucleic acid molecules, glycosylated forms of it, as well as multimeric forms, such as dimers, trimers, and so forth. Also a part of the invention are multimers, such as dimers, which contain at least one protein molecule of the invention, and at least one, different protein molecule. Preferably, this different protein molecule is a cytokine, such as IL-10. Also included as a feature of the inventions are constructs, such as fusion proteins, where all or a part of the proteins described supra are linked in some fashion, such as in a fusion protein, to at least one additional protein or peptide, or amino acid sequence. The "fusion partner" may be, for example, a molecule which provides a recognizable signal, either directly or indirectly, such as a FLAG peptide,  $\beta$ -galactosidase, luciferase, and so forth. These fusion partners are preferably joined to the molecule which is described supra at the N- and/or C- terminus of the protein; however, it is to be understood that there are many techniques known for joining molecules to amino acids, and any and all of these methodologies can produce constructs which are a part of the invention.

The individual protein molecules of the invention, as noted supra, will preferably have a molecular weight of from about 17 to about 30 kilodaltons, as determined by SDS-PAGE. In multimeric forms, the molecular weight of the complex will, of course, vary, but the TIF molecules contained therein will each have a molecular weight of about 17 to 30 kilodaltons, as determined by SDS-PAGE.

The proteins preferably consist of at least about 120 and no more than about 200 amino acids. Preferably, the amino acids sequences consists of or comprises all or part of the amino acid sequences encoded by SEQ ID NOS: 7, 8, 9, 24 or 25. More preferably, the amino acid sequence contains all but about the first 40 amino acids encoded by said SEQ ID's. Even more preferably, it contains all but about the first 20 amino acids encoded by these sequences. Most preferably, the protein comprises amino acids set forth at SEQ ID NO: 27 or 28.

It will be appreciated by the skilled artisan that the proteins encoded by the above recited nucleic acid molecules are a feature of the invention, and may be used to produce

antibodies, in accordance with standard protocols. Such antibodies, in monoclonal and polyclonal form, constitute a further feature of the invention as do fragments of said antibodies, chimeric forms, humanized forms, recombinant forms, and so forth. Also a feature of the invention are immunogens, comprising all or a part of the amino acid sequence protein molecules of the invention, preferably combined with an adjuvant, such as Complete or Incomplete Freund's Adjuvant. Portions of the protein sequences may be linked to other molecules, such as keyhole limpet hemocyanin, to render them more immunogenic. These antibodies can be used, e.g., to determine if the proteins of the invention are present. This is a further feature of the invention, as is now explained. It has been shown, in the examples, that the nucleic acid molecules of the invention were expressed in the presence of the IL-9. Hence, a further feature of the invention is a method to determine if IL-9 is or has been present, wherein one detects either the proteins of the invention, using antibodies for example, or mRNA using the nucleic acid molecules of the invention, as probes. The mRNA can be determined directly, or in the form of cDNA. Such probes may or may not be labeled, as a matter of choice for the user. Hence, one can determine, for example, if, following administration of IL-9, the cytokine is still efficacious, by determining if the nucleic acid molecule of the invention is present. This type of assay can be adapted, for quantitative studies, wherein one determines, for example, either if a cell is sensitive to IL-9, and if so, how sensitive it is. One can also use the proteins of the invention to phosphorylate STAT proteins such as STAT1, STAT3 and/or STAT 5. This in turn results in dimerization of the STAT protein, followed by migration to the nucleus to provoke the effect that these STAT proteins have on cells.

One could also use these molecules to test the efficacy of IL-9 agonists or antagonists when administered to a subject, such as a subject suffering from lymphoma, an immune system disorder such as an allergy, acquired immune deficiency syndrome, autoimmune diabetes, thyroiditis, or any of the other conditions described in, e.g., US Patent No. 5,830,454; 5,824,551, and pending application Serial No. 08/925,348, filed on September 8, 1997 now allowed, all of which are incorporated by reference. The molecules can also be used to mediate the role of IL-9 in these and other conditions. To elaborate, since IL-9 induces TIFs, the TIFs are useful as IL-9 activity mediators. Thus, a further aspect of the invention is a method to determine activity of endogenous IL-9, such as in situations where

excess IL-9 activity is implicated, such as asthmas, allergies, and lymphomas. One can also block or inhibit IL-9 activity by blocking or inhibiting TIF or TIF activity, using, e.g., antisense molecules, antibodies which bind to TIF, or other antagonists of these molecules. For example, muteins of TIF, which bind to the TIF receptor but do not activate it, thereby inhibiting IL-9 induced activity, are a feature of the invention. Examples of conditions which can be treated by the use of such TIF muteins are allergies, asthma, and so forth. Muteins in accordance with the invention can be made in accordance with, e.g., Weigel, et al, Eur. J. Biochem 180(2):295-300(1989) and Epps, et al, Cytokine 9(3):149-156(1997), both of which are incorporated by reference. Such muteins can be used in the treatment of asthma, allergies, or both. Further, it will be clear to the skilled artisan that the models set forth, supra, can also be used to screen for appropriate muteins/ The ability to regulate IL-9 activity is important in conditions such as those listed supra, as well as conditions such as apoptosis, including cortisol induced apoptosis, conditions involving the nuclear expression of BCL-3, since IL-9 is known to induce such expression, and so forth. "Antibodies," as used herein, refers to any portion of an antibody which binds to TIF, including chimeric and humanized antibodies.

Another feature of the invention relates to the ability of the TIF type molecules of the invention to either promote regeneration or inhibit differentiation of tissue types on which the molecules are active. As was shown, supra, the TIF molecules target various cancer and normal cell lines (i.e., mesangial and neuronal cells, as well as melanoma and hepatoma cells). Hence, one can stimulate regeneration of tissue via, e.g., adding an amount of a TIF type molecule to a sample in need of regeneration of a tissue acted on by the TIF molecule. This approach can be used both in vitro, and in vivo. Similarly, antagonists of TIF may be added when the situation is one where the aim is to inhibit differentiation of a particular type of tissue, such as melanoma or hepatoma.

The genes which encode TIF, as noted in Example 25, supra, are located on chromosome 12. This chromosome is associated with asthma, as is known in the art. Hence, a further embodiment of the invention is a method for determining susceptibility to conditions such as, or related to asthma, by determining if aberrations, such as polymorphisms, deletions, additions, etc., are present at the site of the TIF gene. Such aberrations may be an indicia of susceptibility to, or of the presence of, asthma, an allergic condition, or one or more related conditions. The ability to detect aberrations in a DNA sequence is well known in the art, and

such methods need not be set forth herein. Preferably, the aberration or aberrations is detected via standard techniques, such as PCR, using the methodologies and primers referred to supra.

Other features of the invention will be clear to the artisan and need not be discussed further.

- 5       The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

**Claims**

1. An isolated nucleic acid molecule which encodes a T cell derived inducible factor, the complementary sequence of which hybridizes, under stringent conditions, to at least one of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO:25.
2. The isolated nucleic acid molecule of claim 1, wherein said isolated nucleic acid molecule encodes a protein having the amino acid sequence of the protein encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO: 25.
3. The isolated nucleic acid molecule of claim 1, wherein said molecule is cDNA.
4. The isolated nucleic acid molecule of claim 1, wherein said molecule is genomic DNA.
5. The isolated nucleic acid molecule of claim 2, the nucleotide sequence of which consists of the nucleotide sequence SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 29, SEQ ID NO: 24 or SEQ ID NO:25.
6. The isolated nucleic acid molecule of claim 4, having the nucleotide sequence of SEQ ID NO: 25.
7. An isolated nucleic acid molecule which encodes the protein encoded by the isolated nucleic acid molecule of claim 1.
8. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.



9. Expression vector comprising the isolated nucleic acid molecule of claim 2, operably linked to a promoter.
10. Expression vector comprising the isolated nucleic acid molecule of claim 3, operably linked to a promoter.
11. Expression vector comprising the isolated nucleic acid molecule of claim 4, operably linked to a promoter.
12. Expression vector comprising the isolated nucleic acid molecule of claim 5, operably linked to a promoter.
13. Expression vector comprising the isolated nucleic acid molecule of claim 6, operably linked to a promoter.
14. Recombinant cell comprising the isolated nucleic acid molecule of claim 1.
15. Recombinant cell comprising the isolated nucleic acid molecule of claim 2.
16. Recombinant cell comprising the expression vector of claim 8.
17. Recombinant cell comprising the expression vector of claim 9.
18. Recombinant cell comprising the expression vector of claim 10.
19. Recombinant cell comprising the expression vector of claim 11.
20. Isolated protein encoded by the isolated nucleic acid molecule of claim 1, and having a molecular weight of about 17-30 kilodaltons as determined by SDS - PAGE.

21. The isolated protein of claim 20, comprising at least 120 amino acids of the protein encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.
22. The isolated protein of claim 21, comprising at least all but the 40 N terminal amino acids encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.
23. The isolated protein of claim 22, comprising at least all but the 20 N terminal amino acids encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.
24. Antibody which specifically binds to the isolated protein of claim 20.
25. The antibody of claim 24, wherein said antibody is a monoclonal antibody.
26. A method for determining effectiveness of interleukin-9 on a cell, comprising contacting said cell with an agent specific for at least one of (i) an isolated nucleic acid molecule which encodes a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO: 25 and (ii) a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29,SEQ ID NO: 24 or SEQ ID NO: 25 and determining interaction of said agent with (i) or (ii) as a determination of effectiveness of interleukin-9 on said cell.
27. The method of claim 26, wherein said agent is an antibody which specifically binds to (ii).

28. The method of claim 26, wherein said agent comprises the isolated nucleic acid molecule of SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 29, SEQ ID NO:24, or SEQ ID NO: 25.
29. A method for stimulating activation of a STAT protein comprising administering an amount of the protein of claim 20 sufficient to stimulate activation of said STAT protein.
30. The method of claim 29, wherein said STAT protein is STAT1 , STAT3 or STAT 5.
31. A method of inhibiting activation of a STAT protein, comprising administering an amount of an antagonist of the protein of claim 20 sufficient to inhibit stimulation of expression of said STAT protein by said protein.
32. The method of claim 31, wherein said STAT protein is STAT1 , STAT3 or STAT 5.
33. A method for determining presence of TIF in a sample, comprising contacting said sample with an agent which binds to TIF or a nucleic acid molecule encoding TIF, and determining said binding as a determination of TIF in said sample.
34. The method of claim 33, wherein said agent is an antibody.
35. The method of claim 33, wherein said agent is a nucleic acid molecule.
36. A method for screening to determine if a substance influences IL-9 activity, comprising adding said substance to a sample of TIF producing cells, in the presence of IL-9, and determining production of TIF, wherein a difference in production of TIF by said cells as compared to production of TIF by said cells in presence of IL-9 but not said substance indicates said substance influences IL-9 activity.

37. The method of claim 36, wherein said substance is an IL-9 inhibitor or antagonist, said method further comprising determining lower levels of TIF production by said cells in the presence of said substance as compared to its absence.
38. The method of claim 36, wherein said substance is an IL-9 activator, said method further comprising determining higher levels of TIF production by said cells in the presence of said substance as compared to its absence.
39. A method for determining an aberrant level of IL-9 activity in a subject, comprising determining level of TIF in a subject and comparing said level to a normal level, differences therebetween being indicative of an aberrant level of IL-9 in said subject.
40. The method of claim 39, wherein said aberrant level is excess endogenous IL-9.
41. The method of claim 39, wherein said aberrant level is insufficient endogenous IL-9.
42. The method of claim 40, wherein said subject suffers from asthma, an allergy, or lymphoma.
43. A method for inhibiting IL-9 induced activity in a subject in need thereof, comprising administering an amount of a TIF inhibitor sufficient to inhibit IL-9 induced activity.
44. The method of claim 43, wherein said TIF inhibitor is an antisense molecule.
45. The method of claim 43, wherein said inhibitor is an antibody.
46. A method for treating a subject suffering from asthma or an allergy, comprising administering to said subject an amount of a TIF mutein sufficient to alleviate said asthma or allergy.
47. A method for determining if a mutein of TIF is therapeutically useful, comprising contacting a cell which produces IL-9 with said mutein, and determining effect of said

mucin on production of IL-9, reduction thereof being indicative of possible therapeutic efficacy for said mucin.

48. A method for determining susceptibility to a condition characterized by aberrant expression of TIF, comprising determining nucleotide sequence of a TIF gene of a subject believed to possess an aberrant TIF gene, presence of an aberrant TIF gene being indicative of possible susceptibility to asthma or allergy.
49. The method of claim 48, comprising contacting a sample taken from said subject with a pair of oligonucleotide primers which amplify said TIF gene.

ed May 28 07:47AM (02:24) on Right: in 7) for 'WHO1030' ..... WORK. I p. nted image 80029644 on May 28 08:40AM  
 28.MAY.1999 11:50 INSILCO INSTITUTE 7629465 INSITU-LUNO.518 P.P.?

# Sequence homology between human and mouse TIF

Seq ID NO: 21<sub>mtif</sub> 40

Seq ID NO: 22<sub>htif</sub>

MAVQLQKSMGSLMGSTLARSCLLHAIWAQKANAALGVNTRC  
 \*\*\*\*\*  
 MANLQKSVSSELMGSLTNTSCCLLHAIWVGGNAAPLSSDC

mtif

htif

KLEVSNEPQDPYLVNRTMHLAKERSLADNNTDVRLLIGKKLF  
 \*\*\*\*\*  
 RLDKSNFQQPYLTNRTPHLAKERSLADNNTDVRLLIGKKLF

mtif

htif

HGVSAKXDOCYLNEKQVLNRTLEQVLPQSDRRQPYMQEVVF  
 \*\*\*\*\*  
 HGVSMSEKRCYLMKQVLNRTLEQVLPQSDRRQPYMQEVVF

mtif

htif

PTTFLBNQLSSCHISGDIQNICKWVRRLLKGFVKKLGESGCH  
 \*\*\*\*\*  
 FLARLSNRSLSTCHISGDDLHLORTVQKLPFVKKLGESGCH

mtif

htif

KKAIGELDLLFMSLRNACV  
 \*\*\*\*\*  
 KKAIGELDLLFMSLRNACI

Figure 1



## TIFalpha cDNA (SEQ ID NO: 7)

taaacaggctctccctcacttalcaacigtgacactgtgcatctctgATGGCTGTCCTGCAGAAATCTATGAGTTT  
TTCCCTTATGGGGACTTTGGCCGCCAGCTGCCTGCTTCTCATTGCCCTGTGGGCCCAGGAGGCCAAA  
TGCGCTGCCCCGTCA  
ACACCCGGTGCAAGCTTGAGGTGTCCAACCTCCAGCAGCCGTACATCGTCAACCGCACCTTTATGCT  
GGCCAAGGAGGCC  
AGCCTTGAGATAACAACACAGACGTCCGGCTCATCGGGGAGAACTGTTCCGAGGAGTCAGTGCT  
AAAGATCAGTGCTA  
CCTGATGAAGCAGGTGCTCAACTTCACCCTGGAAGACGTTCTGCTCCCCCAGTCAGACAGGTTCCA  
GCCCTACATGCAGG  
AGGTGGTACCTTTCCTGACCAAACCTCAGCAATCAGCTCAGCTCCTGTACATCAGCGGTGACGACCA  
GAACATCCAGAAG  
AATGTCAGAAGGCTGAAGGAGACAGTGAAAAAGCTTGGAGAGAGTGGAGAGATCAAGGCGATTGG  
GGAACCTGGACCTGCT  
GTTTATGTCTCTGAGAAATGCTTGCGTCTGAgcgagaagaagclagaaaacgaagaactgctccttctgcttctaaaa  
agaacaataagatccctgaatggacttttactaaaggaaagtgagaagctaacgtccatcatcattagaagattcac  
atgaaacctggctcagtgaaaaagaaaatagtgcaagttgcatgagaccagagglagactgataaccacaaagat  
tcattgacaatatltatgtcactgatacaacagaaaaataatgtacttaaaaaattgttgaaaggagggtacc  
tctcattcctttagaaaaaagcttagtaactcattccatccaatattatataatgtaagttattattataa  
gtatacatttattatgtcagttattaatatggatttattatagaacattatcgtatgatattagataagg  
caataatatltatgacaataacltgaaacaagatatctaggctttaataaacacalggatatacaaaaaaaaaa

## TIFalpha Protein (SEQ ID NO: 10)

MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPVNTRCKLEVSNFQQPYIVNRTFMLAKEASLADNNT  
DVRLLGEKLF  
RGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVPFLTKLSNQLSSCHISGDDQNIQKNVRLK  
ETVKKLGESGE  
IKAIGELDLLFMSLRNACV

## TIFbeta cDNA (SEQ ID NO: 8)

aacaggctctcctcagttatcaactttgacactgtgcatcggtgATGGCTGTCCTGCAGAAATCTATGAGTTTTT  
CCCTTATGGGGACTTTGGCCGCCAGCTGCCTGCTTCTCATTGCCCTGTGGGCCCAGGAGGCCAAATG  
CGCTGCCCCATCAAC  
ACCCGGTGCAAGCTTGAGGTGTCCAACCTCCAGCAGCCGTACATCGTCAACCGCACCTTTATGCTG  
GCCAAGGAGGCCAG  
CCTTGAGATAACAACACAGACGTCCGGCTCATCGGGGAGAACTGTTCCGAGGAGTCAGTGCTAA  
GGATCAGTGCTACC  
TGATGAAGCAGGTGCTCAACTTCACCCTGGAAGACATTCTGCTCCCCCAGTCAGACAGGTTCCGGC  
CCTACATGCAGGAG  
GTGGTGCCTTTCCTGACCAAACCTCAGCAATCAGCTCAGCTCCTGTACATCAGTGGTGACGACCAGA  
ACATCCAGAAGAA  
TGTCAGAAGGCTGAAGGAGACAGTGAAAAAGCTTGGAGAGAGCGGAGAGATCAAAGCGATCGGGG  
AACTGGACCTGCTGT  
TTATGTCTCTGAGAAATGCTTGCGTCTGAgcgagaagaagclagaaaacgaagaactgctccttctgcttctaaaaag  
aacaataagatccctgaatggacttttactaaaggaaagtgagaagctaacgtccatcatcattagaagattcacat  
gaaacctggctcagtgaaagagaaaaatagtgcaagttgcatgagaccagagglagactgataaccacaaagattc  
atgacaatatltatgtcattgataatgaacagaaaaagtatgtacttaaaaaattgttgaaaggagggtaccctc

SEQ ID NO: 8 (CTD)

tcattcctctagaagaaaagccatglaacttcattccataaccaatactttatataatgaagttattataagt  
atacattttattatgtcagtttataataggattttatagaaaaattatcigatgtgatattgagataaagc  
aaataatattatgataaactatagaacaagatatcttaggcttaataaacacalgaatacataaa

TIFbeta Protein (SEQ ID NO: 11)

MAVLQKSMFSLSMGTAAASCLLLIALWAQEANALPINTRCKLEVSNFQQPYIVNRTFMLAKEASLADNNTD  
VRLIGEKL  
RGVSAKDQCYLEMKQVLNFTLEDILLPQSDRFRPYMQEVPFLTKLSNQLSSCHISGDDQNIQKNVRLKE  
TVKKLGESGE  
IKAIGELDLLFMSLRNACV

TIFalpha Genomic Sequence (SEQ ID NO: 9)

GTCTATCACCTGCTTAAGATTCTTCTAATTTATAAAAAAACTATTTCTTAAATGAAAAGCAACCAGA  
GCACGTATTTA  
TAGCATGGTGTCTGACCATGCAGGTACAGAGTGGAATGGTAAGAGGCGCTATTATCAGCATTAAACC  
AACATGTTAATGT  
TTTCTTCTGGCAAGCAAACCTTGAAATCTATGTCTTAAACAATCTTCAAGCCTCTAATATAGTGCTAACG  
ACTGGAGTCCG  
CTGCTGTCCAACAGAGCTCTTGAGCACGCTCTCCTCTGTTTGCAATTTTATGTTCTTTGATCGACTCC  
CCAACCTCTCAC  
CTTCGGCTCCTGATGGCCACCTTTCAACTTTCTGCATTTATGAACTCCATGTTTTAATCTTTTTATTAA  
AATATTCACAC  
AATCAGTGTTTGTGCAAGTCTGTTTCACCCACATGTATGTCTGTGCACCAAGTGCTGCCTGGTGCTT  
GTGGGGGCAAGGA  
GCAGGAGAGGGTGCCCTGGCACCGGAGTCACGGATGGTTGTGAGCCACCATGAGGATGCTGGGAG  
TTAGACCCAGGTCCT  
CCAGAAAGTGACAGCAAATGCTCTTAACACACGCAGGCATTTCTCTCTCCAGCCCCAACATGAGTGCT  
TTAGATTCCACC  
TAGAATAGAGATCTGATGGCTTCACTCACTGCCACCTCCCCTTGCATCTTTCTGCCAAGGAACACC  
AAAAAGCAAGAAT  
CCCCACACTGCTTTTCGCTCCTCAAGTCTGCACCTCTCAACAGGTCAAGATTCTCCAGTGTCCTCTA  
ACACTTTCCCCAG  
TGTCCCTCTAACACTTTCTCCAGTGTCCTCTAACACTTTCTCCAGTGTCCTCTAACACTTTTGATCT  
CAATTAGCTGA  
GGGGAGAAAGATCTCACACAGTGATTTTCATGACTTCGCGTTCTAGTCTAGATGTAGGCATTTGCGT  
GTCAGTCTAGGGT  
AGGCGTCTGCTCCCGCTGCTTAGGAAAGACTTTCCTAGTCTAGTTGTCAGGTGCTATCTGGGATTCA  
GTGTACATACAAT  
GCAAAAAATCCCAGTATTTTGTAATTCTCTTCTTCAACTATCCATCTATATAGTATGTTATTGTAGGC  
TCATTTAAAAA  
TAATATTTTGAGACTTATGCTTGCAQAAGTAAATGTCAGAGAATTAGCAAATGTATAGTATTATTTTA  
TTTTAAAAA  
TCTATGCTTAAATGTCTATTAGATTGTTCACTACCGATATTTCCAACTTAACTTGACCTTGGCTATG  
ATTTCAACCTT  
TGTATTTGCATCTACCATAACAGTCTCTGAACCAGAACATTCTGTGGCAATGGGAGCTGTGAAGAAA  
GCCAACATTCTTA  
TAAAAAATAACAGCTAGTTATAGTTTAGGATTCCATATACTAAAAAATAGAGATATAATTATTT  
TAAAAATTGA

AATAATCTCCAAGTTTTATTATGGCTTATTTCAAAGCACAGAATATAGGACACGGGTCTTTTATTTCT  
GGTCACTTCTA  
AAGAGATAAGAATCTATGAAGTTGGTGGGAAAATGAGTCCGTGACCAAACGCTGACTCAATAGCTA  
CGGGAGATCAAAG  
GCTGCTCTACTCAATCAGAATCTACTACGGCAAAGCCATGGCTTTCTTTGAAAACCGTGTTTAGAAGA  
TTTCTGGGATTT  
GTGTGCAAAAGCACCTTGTTGGCCCTCACCGTGACGTTTTAGGGAAGACTTCCCATCTCTCAAGGTG  
GGAAGGCTTGGAG  
GTGGTGTCTTGTGGCCTCCTATGGTGGTTAGGTACTTCTCAGAAGACAGGACTGGAAATTAGATAAT  
GTCTGATGTCATA  
TCATTACAATACCAAAAAACCCCTGGTGTCCCGATGGCTATAAAAGCAGCAACTTCTGCCTCTCCC  
ATCACAAGCAGAG  
ACACCTAAACAGGTAAGCACTCAGACCTCTACAGACAATCATCTGCTTGGTACCATGCTACCCGACG  
AACATGCTCCCT  
GATGTTTTTGCCTTTTGTCTCTCACTAACAGGCTCTCCTCTCACTTATCAACTGTTGACACTTGTGC  
GATCTCTGATGG  
CTGTCCTGCAGAAATCTATGAGTTTTTCCCTTATGGGGACTTTGGCCGCCAGCTGCCTGCTTCTCATT  
GCCCTGTGGGCC  
CAGGAGGCAAATGCGCTGCCCGTCAACACCCGGTGCAAGCTTGAGGTGTCCAACCTCCAGCAGCC  
GTACATCGTCAACCG  
CACCTTTATGCTGGCCAAGGAGGTACAGCTGCATCTCTTCTCTCCATACCGCCTTGCCATTTTCTCT  
GAAGCACTTGCA  
AACTCTTTAGGGGCGCTTTATCTCCGCAGGTCTCACTACCTATGTTTTCTGTCTCTTTAGAGACTCTT  
TAAGGACTGGGT  
CTTTTCTATTTCTATTTCAAGGTCTCAGGACCATTTCTATCTTGGCCTTCAGGACACATATACTGAA  
TTTTATCTACA  
GAGGCGCATTTAGAAAGCCACCCACGACTGCAATACTTTCCATTTCTCTGTGCTCTCTTCTGAACTCA  
TACTCTCTTGGC  
TACTCCTGAGACCCACTGCGGACATACATCTCTACTTACAGGCTTTTCTTCCATCTCCTTGTCACCCA  
GGCACTTAGGGT  
TTTCTCTCTTTCAGGCCAGCCTTGCGAGATAACAACACAGACGTCCGGCTCATCGGGGAGAACTGTT  
CCGAGGAGTCAGT  
GTAAGTCCTCACTGTGATGAGCAGGGCTAGCTGCGGGAGCTGGTGGACCCTCTGGGATAGTCTGAC  
GTATGACCCCTGCT  
GCTTCTTGTCTACCTGCAGGCTAAAGATCAGTGCTACCTGATGAAGCAGGTGCTCAACTTCACCCTG  
GAAGACGTTCTGC  
TCCCCCAGTCAGACAGGTTCCAGCCCTACATGCAGGAGGTGGTACCTTTCTGACCAAACCTCAGCA  
ATCAGCTCAGCTCC  
TGTGTAAGTCTGACTCTGGCTACCTATGCTCCTCTCTCTTCTCTTCTATTCCAGTAAGAACCCGAGG  
TCCTGCCCTCTC  
TCTCTTACAAGAGTGAGGAGGGCCTCAGCACCACCACCATCATAGGCCACTTGAAATAGGTCACAA  
AGGCTTTGGCTTC  
AATTGAGTAATACTTTGAGTTTGTATGAGTGAAGCTTTATTTGTTTTATCCATGGAAAGAAATCAACTC  
AAATTCTGTAG  
GATGAGAAAGATGTTGGGAACGAAAAAGGCCTAGATAGAGAAACAGATCTGCTGAGTATAGTACTT  
ATGGGGGGGAGCAG  
GGGGCGATATCCACTGAGTACAAGTACTTGTGGGGAGAGAAATCCACTGAGTACAAGTACTTGTG  
GCATGGAGATCCAC  
TGAGTACAAGTACTTGTGGGGGGAGGGGAATGGCACAGAGCAAAAGTTGAAGGGAAGGAAGATGGA  
GAGGCCTCATGGTTG  
GGGGTGTGAAAGGTCACTCCTTTTCCATGTGATGGAGAGTTAAGAAAAACCACTGTGTGAGTTTGAT  
GTCTTCAGACACC  
CCCAACTATGAAACATATCCACGAGGAGCGGGCAGACTGTGGGAGACCTGGCATTTAGGGAAGGC  
GCGGCTTTTCACACG

AGAACTTTATGCTCATCTCTTGCTGCTACACTCCCACCTTTGATGAGGTTGAGCTCAGGTTTCGTTTC  
TACCGTTCTTGC  
TACTGGTGGAACTTCAGTAGGATTCCCCAAAGACGAGGACAGCTCTTCTGTAAGGGAGGGACCTG  
GATTCAGTGTCT  
AGAGAACGAAATAGCTCAGAGAATCTAGGTCAACGTGAAATCTAGGTCACAGCGGGCAAAAATGACT  
GAACGCCTCTATT  
CCAGGTGAACGGTCACGTGCCTCAGATATACTGAGGTATTGGGCTCCCACCGGATAAGATTCTGTTA  
GTGAGTCTGCTTT  
TATTTTGCAGCACATCAGCGGTGACGACCAGAACATCCAGAAGAATGTCAGAAGGCTGAAGGAGAC  
AGTGAAAAAGGTAC  
TATTGGCAAGCCACAATACTAAGCCATTGAGTAGGAGACGTGGGGATTCTTTCTCTGCTTCCAGT  
CCCTTCTACTTTG  
TAACATTTTATTTGACTTGTCTACTATCTGGTCCATTACTCGCTTAGCTGCACCTGTATCTAGCTGGGT  
CTATAGATCTT  
TCAATCTGTGTCTAAATTTGTAAGTCACAATTCTGGAGCTAGCAGAAAGCTTAGCTCAGCCAGTCTCA  
TGAGCACTTGCT  
CGGAGGATGGCTTGTGACAGAGTCAATGCTAGAAGACAGCATCCCTGATTCCCAGCTCTGCACTTG  
CCTAGTGGCCATGT  
GTAATTACTTTGGCTTGATTAAGTATTTGGGAAAGCCAGTTCCCACGGACCTACATAATCTGAAGAAC  
CATGCATTGAAA  
ACTAGAAAGCTGGGCACAACTTACTAGAGATGATTTTGGAGCTCATTAAACGGATGCTCTGAAATGT  
GGCAAAATCAAC  
CCAGAATAACAACAAAAGAGCTGGATTGCAAATAGGACAAGTATTTAGAATCACTGGTATTAATAGC  
TATCATCTTAAT  
TAAATATAGGGCCTATATATATATTTAAGATTAAACACAAGAGTGGATAGCCTCCCAATTTACTTGG  
CCTGGTTTCAAA  
AGAGTAAAAATATCAGTCATGGATTAATTATAGTGTGATGAAAGTATGAGATGGAAACCCCTTTCCTTA  
CTTTTACCTTC  
ATTTCTTAGTTTTTTTTTTCTTCACACCCTGATCAAGCCACTAGTAAGCACCTATCTGCTGTGAGCTAT  
TATATGACTTT  
ACAGCAAACAACATTGCTGTGTGGCCTCTTTGGGGAAGGGAACAGGATAGCAGGAGGCTCAGGCTA  
GCAAGTCTGACTTG  
CCCTAAAGCCAGAGGCATGGTTGATAGCAGAGAAAGTGAGGCTCTTCGCAAGTGGGTGTGCTTAAG  
TAATCAGAAACAGG  
AAGGCTCCGGTTGATGGAATTATCAGTAAGATATCTACCCTTATCTCCTTCTATCGAACCTAAATCGT  
CTCTTTTCTTG  
TGTGTAGGCTGATAAACACACTTGTTTTCTTTGAGTGTTGATGGCTTTGTAGATTTTGTAGTCTGCTGC  
CAGTTCTTGT  
AGAGGGTTTGTACCTTGACACCTGGGCTTGGATGTTAGCATGCCAAAGGCACACACTTCTGAATGC  
CTGTGTAAAAGGT  
TATTATTCATTTACTTTGTCTTTGGAAAGGTGAAGCGTGTGTGAGAAAGAACTCACAGGAGATGTGTT  
CTCTGTAGGAAA  
ACTTTTTTTTTCCCTTAAATGCCTATAATCCACTTTCAGTCAACTTTGACTTTTATACCATGCTGTGAC  
ATGAAAGAGT  
GTTTAGGCCCGCTCTCATGGCTCTGGGAAAAGCACCAATAGGGGAAGGAATGTTATGCTGAGAAAT  
CTGACCGGCAGGGA  
AACTGGTCAGAGCTCCCCGAAGACCACCACAGGTGTTAAGTAGGAACAGTCCAGGGTGGGCTCAT  
GTAATAGAATGGAA  
CAGAGCGAGGGAAGATAAGCTACAAAGTTTCATAGGGTCCGGAGTCTTAAAGATACAAAATAGCTGC  
TTGGGCTTCATAA  
CAAAGGAAGTCTGGGAAGGCAGCAAGTGAGAGGGAAATGGAAAGGGAAAAACAGAATGTAGAGG  
ACTTGAACAGCTACA  
AATCCTCTACCAGACGATTTTTCTTGGAAACAATCTAGAAGGTAGTGGATTAGGTGATTGCAGGGGGA  
CTTGCTTTGCCAT

TTGAATCTGGGTTTTTGTCTCTCCATTGAGGTTGAAAGCGTCACCCTTTTTACCCTCGAATGGAGGAG  
GAAAGAAGGGGT  
GTTATGACTCCTACCTGGAGTTTTACTAGTTTACGCAATGGAACAGACACTCGGGACCTCCTCTTGA  
CAAAAAAATGGA  
AACCTGTTGTTTGTCTTGTCTTTGTTCTTTTGTAAAGAAAGCACAGGCAAAGCCCGACCACATGGGTTGA  
ATGTGGGTCTTT  
GAGTCAAGGCTTTTGAGTTGAGCACTCATCAATAGTTGATCATGGTCAGGTGGAGGGCTACCTGTCA  
GGCCGAGCCCTGC  
TGGCTTCGCACTTAACATCTCCAGGTCTCAGTATCACTTCCTGCTACTTAGCACAGTTAGGAGTTGA  
GCAAACCTTTTTT  
TCCAACCCCCACTAAAATTTAATTGACAAAAGACTGTGTAATTTGTGGGATACAGTGTGATAATTGAT  
CTATGTGTGCAT  
TGTGCAAGGTTCAATAAGATAGATTAATAGGCCCATCAACAGCTTTATGGGTGTGAAATGCAAGTAAT  
ATAGGTAGATGC  
CTGTGGTGTCTTAGGTCAGAAAGGCATGATTTTAAGGTCTTGGGCAAATCATATTATACTCATGCTA  
AAAATACATTAT  
GTTGATTATTAATCTTTTAGAGAAGGCTGATACTTGGTTTTGGTGCTCAGCAAGCAAATGTCACCAGC  
TCTTCTAACTG  
GTACCACTTTAGAAAAATGCTACCTGTGCTCAAATTGGTTTTGTATTCTTATTTTCATAGCTTGGAGAGA  
GTGGAGAGATCA  
AGGCGATTGGGGAACTGGACCTGCTGTTTATGTCTCTGAGAAATGCTTGCGTCTGAGCGAGAAGAA  
GCTAGAAAACGAAG  
AACTGCTCCTTCCTGCCTTCTAAAAAGAACATAAGATCCCTGAATGGACTTTTTTACTAAAGGAAAG  
TGAGAAGCTAAC  
GTCCATCATCATTAGAAGATTTACATGAAACCTGGCTCAGTTGAAAAAGAAAATAGTGTCAAGTTGT  
CCATGAGACCAG  
AGGTAGACTTGATAACCACAAAGATTCATTGACAATATTTTATTGTCACTGATGATACAACAGAAAAAT  
AATGTACTTTA  
AAAAATTGTTTGAAAGGAGGTTACCTCTCATTCCCTTTAGAAAAAAGCTTATGTAACCTTCATTTCCATA  
TCCAATATTTT  
ATATATGTAAGTTTATTTATTATAAGTATACATTTTATTTATGTCAGTTTATTAATATGGATTTATTTATA  
GAAACATTA  
TCTGCTATTGATATTTAGTATAAGGCAAATAATTTATGACAATAACTATGGAAACAAGATATCTTAG  
GCTTTAATAAA  
CACATGGATATCATAAATCTTCTGTCTTGTAATTTTCTCCCTTTAATATCAACAATACCATCATCATCA  
TCATTACCCA  
ATCATTCTCATGATTTTCATGCTTGACCCATATTATACTGTAAAGTTGGTTCCTGGAGGCCTGTGGTT  
TTGTGTGTGTTG  
TGTGTGTGTGTGGGGTTATGCATGTGAAAGCCAGAGATGGATATTAGGTGTTCTTCTCTATCAGTCTT  
TGCTTATTATT  
TGAGACAGGGTCTGTCACTGAACCTGTAGCTAGGCTGGCCAACAAGCTCTATTAATTTTTTTTAAGAT  
TAATTAATTATG  
TGTAT

exon 1a: nucleotides 1908-1932

exon 1b: nucleotides 2033-2262

exon 2: 2655-2720

exon 3: 2820-2863

exon 4: 3931-3996

exon 5: 6539-7137



Human TIF cDNA

TGCACAAGCAGAATCTTCAGAACAGGTTCTCCTTCCCCAGTCACCAGTTGCTCGAGTTAGAATTG  
TCTGCAATGGCCGCCCTGCAGAAATCTGTGAGCTCTTTCCTTATGGGGACCCTGGCCACCAGCTG  
CCTCCTTCTCTTGGCCCTCTTGGTACAGGGAGGAGCAGCTGCGCCCATCAGCTCCCACTGCAGGC  
TTGACAAGTCCAACCTCCAGCAGCCCTATATCACCAACCGCACCTTCATGCTGGCTAAGGAGGCT  
AGCTTGGCTGATAACAACACAGACGTTCTGCTCATTGGGGAGAACTGTTCCACGGAGTCAGTAT  
GAGTGAGCGCTGCTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAAGAAGTGCTGTTCCCTC  
AATCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTCCTGGCCAGGCTCAGCAACAGG  
CTAAGCACATGTCATATTGAAGGTGATGACCTGCATATCCAGAGGAATGTGCAAAAGCTGAAGGA  
CACAGTGAAAAAGCTTGGAGAGAGTGGAGAGATCAAAGCAATTGGAGAACTGGATTGCTGTTTA  
TGTCTCTGAGAAATGCCTGCATTTGACCAGAGCAAAGCTGAAAAATGAATAACTAACCCCTTTC  
CCTGCTAGAAATAACAATTAGATGCCCCAAAGCGATTTTT

SEQ ID NO. 24



Human genomic sequence of TIF

8E6 ID NO: 25

[illegible]

TGAGAAATGCCTGCATTGACCAGAGCAAAGCTGAAAAATGAATAACTAACCCCTTTCCCTGCTAGAAATAACAATTAGATGCCCC  
AAAGCGATTTT

TIFbeta Genomic Sequence

(EW ID NO) 29

GAATTCAAGTCCACATGCAATCAATCCGAATACTTTGTAAATTCTCTTCTTCAAATATCCATCTATATA  
GTATAAGTTATTGTAGGATCATTTAAAAATAATGTTTTGAGACTTATGTTTGCACAAGTAAAATGTCAG  
AGAGAATTAGCAAATGTATAGTATTATTTTATTTTAAAAAATCTATGCTTAAAATGTCTATTAGATTGTT  
CACTACTGACATTTCCAACTTAACTTGACCTTGGCTATGATTTCAACCTTTGTATTTGCATCTACCAT  
AACTGTGTGCTCACTTACCATGCTATCCGACGAGCATGTTCCCTGATGTTTTGCCTTTTGCTCTCT  
CGCTAACAGGCTCTCCTCTCAGTTATCAACTTTTGACACTTGTGCGATCGGTGATGGCTGTCCTGCA  
GAAATCTATGAGTTTTTCCCTTATGGGGACTTTGGCCGCCAGCTGCCTGCTTCTCATTGCCCTGTGG  
GCCCAGGAGGCAAATGCGCTGCCCATCAACACCCGGTGCAAGCTTGAGGTGTCCAACTTCCAGCAG  
CCGTACATCGTCAACCGCACCTTTATGCTGGCCAAGGAGGTACAGCTGCATCTCTTTCTCTCCATAC  
CGCCTTGCCATTTCTCTGAAGCACTTGCAAACCTTTAGGGGCGCTTTATCTCCGCAGGTCTCACTA  
CCTATGTTTTCTGTCTCTTTAGAGACTCTTTAAGGACTGGATCTTTTCTATTTCTATTTCAAGGTCTC  
AGGACCATTTCCTATCTTGGCCTTCAGGACACATATACTGAATTTTATCTACAGAGGCGCGTTTAGAA  
AGCCACCCACGACTGCAATACTTTCCATCCTGTTGTGCTCTCTTCTGAACCTCATACTCTCTTGGCTAC  
TCCTGAGACCCACTGCGGACATACATCTCTACTTACAGGCTTTTCTTCCATCTCCTTGTCACCCAGGC  
ACTTAGGGTTTTCTCTCTTTCAGGCCAGCCTTGCAAGATAACAACACAGACGTCCGGCTCATCGGGGA  
GAA  
ACTGTTCCGAGGAGTCAGTGTAAGTCCTCACTGTGATGAGCAGGGCTAGCTGCGGGAGCTGGTGGA  
CCCTCTGGGATAGTCTGACGTATGACCCCTGCTGCTTCTTGTCTACCTGCAGGCTAAGGATCAGTGC  
TACCTGATGAAGCAGGTGCTCAACTTCACCCTGGAAGACATTCTGCTCCCCCAGTCAGACAGGTTCC  
GGCCCTACATGCAGGAGGTGGTGCCCTTTCCTGACCAAACCTCAGCAATCAGCTCAGCTCCTGTGTAA  
GTCTGGCTCTGGCTACCTATGCTCCTCTCTCTTCTTCTATTCCAGTAAGAACCCGAGGTCTGCTG  
CCTCTCTCTCTTCAAGAGTGAGGAGGGCCTCAGCACCACCACCATCATAGGCCACTTGAAATAG  
GTCACAAAGGCTTTGGCTTCAATTGAGTAATACTTTGAGTTTGTATTAGTTAAGCTTTATTTGTTTTAT  
CCATGGAAAGAAATCAACTCAAATTCTGTAGGATGAGAAAGATGTTGGGAACGAAAAAAGGCCTAGA  
TAGAGAAACAGATCTGCTGAGTACAGTACTTATGGGGGGGGGGGGCAGGGGGCGATATCCACTGA  
GTCCAAGTACTTGTGGGAGAGAAATCCACTGAGTACAAGTACTTGTGGGGGAAGGAATGGCACAG  
AGCAAAAGTTGAAGGGAAAGAGGAAGATGGAGAGGCCTCAATGTTGGGGGTGTGAAAGGTCACTCC  
TTTTCCATGTGATGGAGAGTTAAGAAAAATCAGTGTGTGAGTTTGTATGTCTTCAGACACCCCACTA  
TGGCAGACTGTGGGAGACCTGGCATTAGGGGAAGGCGCGGCTTTTACACGAGAACTTTATGCTC  
ATCTCTTGTGCTACACTCCACCTTTGATGAGGTTAAGCTCAGGTTTCGTTTCTACCGTTCTTGCTAC  
TGGTGGAAACTTCAGTAGGATTCCCCAAAGACGAGGACAGCTCTTCTGTAAGGGAGGGACCTGGAT  
TTCAGTGTCTAGAGAACGAAA  
TAGCTCAGAGAATCTAGGTCAACGTGAAATCTAGGTCACAGCGGGCAAAAATGACTGAACGCCTCTA  
TTCCAGGTGAACGGTCACGTGCCTCAGATATACTGAGGTATTGGGCTCCACCGGATAAGATTCTGT  
TAGTGAGTCTGCTTTTATTTTGCAGCACATCAGTGGTGACGACCAGAACATCCAGAAGAATGTCAGA  
AGGCTGAAGGAGACAGTGAAAAAGGTACTATTGGCAAGCCACAATACTAAGCCATTCAGTAGGAGA  
CGTGGGGATTCTTTCTCTGCTTCCAGTCTCTTCTACTTTGTAACATTTTCTTTGACTTGTCTACTGT  
CTGGTCCATTACTCACTTAGCTGCACCTGCATCTAGCTGGGTCTATAGATCTTTCAATCTGTGTCTAA  
ATTTGTAAGTCACAATTCTGGAGCTAGCAGAAAGCTTAGCTCAGCCAGTCTCATGAGCACTTGCTCG  
GAGGATGGCTTGTGACAGAGTCAATGCTAGAAGACAGCATCCCTGATTCCCAGCTCTGCACCTGCCT  
AGTGGCCACGTGTAATTACTTTAGCCTGATTAAGTATTTGGGAAAGCCAATTCCCACCGACCTACATA  
ATCCGAAGAAGCATGCATTGAAAAGCTAGAAAGCTGGGCACAACTTACTAGAGATGATTTTGTAGCT  
CATTAACTGATGCTCTGAAATGTGATCAAATCAACCCAGAATAACAACAAAAGAGCTGGATTTGCAA  
ATAGGACAAGTATTTAGAATCACTGGTATTAACAGCTGTCATCTTAATTAATAATATAGTGTCTATTTAG  
CTGCCTATTTAAGATTAAACACAAGAGTGGATAACTTCCCAATTTACTGGGCCTGGTTTCAATAGAGT  
AAAAATATCAGTCATAGATTAAATTATAGTGTGATGAAAGTATGAGTTGGAAACCCTTTCCTTACTTTTT  
ACCTTCATTTCTTAGTTATTATTTTTTTTTCTTACACCCTGATCAAGCCACTAGTAAGCACCTATCTG  
CTGCGA  
GCTATTATATGACTTTACAGCAAACAACATTGCTGTGTGGCCTCTTTGGGGAAGGGGAACAGGATAGC  
AGGAGGCTCAGGCTAGCAAGTCTGGACTCAACCTAAAGCCAGAGGCATGGTTGATAGCAGAGAAAG

TGAGGCTCTTCACAAGTGGGTGTGCTTAAGTAATCAGAAACAGGAAGGCTCTGGTTGATGGAATTAT  
CAGTAAGATATCTACCCTTATCTCCTTCTTCTATAGAAGCTAAACCGTCTCTCCTTCTTGTGTGTAGG  
CTGATAAACACGCTTGTGTTTCTTTGAGTGTTTCATGGCTTTGCAGATTTTCAGTGCTCTGCCAGTTCTT  
GTTAGAGGGTTTGTACCTTGACACCTGGGCTTGGATGTTAGCATGCCAAAGGCACACACTTCTGAA  
TGCCTGTGTAAAAGGTTATTATTCATTTACTTTGTCTTTGGAAAGGTGAAGTGTGTGTGAGAAAGAAC  
TCACAGGAGATGTATTCTCTGTAGGAAAACTTTTTTTCCCCTTAAAGCCTATAATCCACTTTTCAGTC  
AACTTTGACTTTTATACCATGCTGTACATGAAAGAGTGTGTTAGGCCCGCTCTCGTGGCTCTGGGAA  
AAGCACCAATAGGGGAAGAAATGTTATGCCGAGAAATCTGACTGGCAGGGGAACTGGGTCAGAGCT  
CCCCAAAGACCACTACAGGTGTTAAGTAGGAACAGTCGAGGGTGGGTTTCATATAATAGAATGGAACA  
GAGGGAGGGGAAGATAAGCTACAAAGTTTCATAGGGTCCTAAGTCTTTAAGATACAAAATAGCTGGTT  
GGGCTTCATAACAAAGGAAGTCTGGGAAGGCAGCAAGCATTGAGAGGGAGATGGAAAGGGGAAAAAA  
CAATGTAGAGGATTTGAAAAGCTACAAATCCTCCACGAGAGGATTTTTCTTGGAGGAATCTAGAACA  
AGGGTGGTGGATTAGGTGGATCGCAGAAGGACTTGCTTTGCCATTTGAATCTGGGTTTTTGTCTCTC  
CATTGAGGTTGAGA  
GCGTCACCCTTTTTTACCCTGGATAGGAGGAGGAAAGAAGGGGTGTTTTGACTCCTACCTGGAGTTT  
TACTAGTTTACGCAATGGAACAGACACTCGGGACCTCCTCTTGACAAGAAAAAAGGA  
AACCTGTTGTTTCTCTTGTGTTGTTCTTTTGTAAAGAAAGCACAGGCAGCTGGGCATGGTGGCCCATG  
CCTTTAATCCCAGCATTGTTGGGAGGCAGAGGCAGGTGACTTTCTAAATTCAAGGCCAGCCTGGTCTAC  
AAAGTGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCTGTCTCGGGAAAAAAGAAAG  
AAAAGAAAAGAAAAGAAAGAGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGA  
GGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGAGAGGAGA  
AAGAGAAG  
AGAAAAGAAAAGAAAAGCAAGCAAGCAAGCAACTGGCAAGCATGCCACATGGGACGTATGTGG  
GTCTTTGAGACAAGGCTTTTGAATTGAGCGCTCATCAATAGTTGATCATGGTCAGGTGGAGGGCTAC  
CTGTCAAGGCCGAGCCCTGCTGGCTTAGCACTTAACATCTCCAGGTCTCAGTATCACTTCCTGCTGCT  
TAGCACAGTTAGGAGTTGAGCAAACCTTTTTTTTCCAACCCCCACTAAAATTTAATTTACAAAAGGCAG  
TGTAATTTGTGGGATACAGTGTGATAATTGATCTATGTGTGCATTGTGCAAGGTTCAATAAGGTAGAT  
CAATAGGCCCATCAACAGCTTTATGGGTGTGAAATGCAAGTAATATAGGTAGATGCCTGTGTGTCCT  
TAGGTGAGAAAGGCATGATTTTAAGGTCTTGGGCAAATCATATTATACTCATGTAAAAATGCATTAT  
GTTGATTATCAATCTTTTAGAGAA  
GGCTGATACTTGGTTTTGGTGCTCAGCAAGCAAATGTCACCAGCTCTTTCTAACTAGTACCACTTTAG  
AAAATGCTACCCGTGCTCAAATTGTTTTGTATTCTTATTTTCATAGCTTGGAGAGAGCGGAGAGATCA  
AAGCGATCGGGGAAGTGGACCTGCTGTTTATGTCTCTGAGAAATGCTTGCGTCTGAGCGAGAAGAA  
GCTAGAAAACGAAGAACTGCTCCTTCTGCTTCTAAAAGAAACAATAAGATCCCTGAATGGACTTTT  
TTACTAAAGGAAAGTGAGAAGCTAACGTCCACCATCATTAGAAGATTTACATGAAACCTGGCTCAG  
TTGAAAGAGAAAATAGTGTCAAGTTGTCCATGAGACCAGAGGTAGACTTGATAACCACAAAGATTCA  
TTGACAATATTTTATTGTCAATTGATAATGCAACAGAAAAAGTATGTACTTTAAAAAATTGTTTGAAGG  
AGGTTACCTCTCATTCTCTAGAAAGAAAAGCCTATGTAACCTTCAATTCATAACCAATACTTTATATAT  
GTAAGTTTATTTATTATAAGTATACATTTTATTTATGTGAGTTTATTAATATGGATTTATTTATAGAAAA  
TTATCTGATGTTGATATTTGAGTATAAAGCAAATAATTTATGATAATAACTATAGAAACAAGATATCT  
TAGGCTTTAATAAACACATGAATATCATAAATCTTCTGTCTTGTAATTTTTCTCCCTTTAATATCAACAA  
TACCATCATCGTCATCATTACCCAATCATTCTCATGACTTCATGCTTGACTCATATTATCTGGTAAAGT  
TTG

exon 1: nucleolides 355-584

exon 2: 976-1041

exon 3: 1141-1284

exon 4: 2204-2269

exon 5: 5225-5824



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24424

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 424/85.1, 85.2; 435/6, 7.1, 69.1, 252.3, 320.1; 530/351, 388.2;

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

medline, patents, caplus, embase, biosis

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 5,908,839A (LEVITT ET AL) 01 June 1999 (01.06.99), see entire document, especially columns 7 and 8.	33-49
Y	US 5,814,517 A (SEIDEL ET AL) 29 September 1998 (29.09.98), see entire document, especially abstract and col 17, lines 15-66.	35,43 and 44
Y	ZHU et al. Critical Cytoplasmic Domains of Human Interleukin-9 Receptor alpha chain in Interleukin-9-mediated Cell Proliferation and Signal Transduction. Journal of Biological Chemistry, 22 August 1997, Vol. 272, No. 34, pages 21334-21340, especially page 21334, column 2, 2nd paragraph, page 21339, last paragraph, and page 21340, first paragraph.	33-49



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*C*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 14 JANUARY 2000	Date of mailing of the international search report 08 MAR 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Amy DeCloux Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24424

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DEMOULIN et al. A Single Tyrosine of the Interleukin-9 (IL-9) Receptor is Required for STAT Activation, Antiapoptotic Activity, and Growth Regulation by IL-9. Molecular and Cellular Biology. September 1996, Vol.16, No.9, pages 4710-4716.	33-49
A, P	DEMOULIN et al. Distinct Roles for STAT1, STAT3, and STAT5 in Differentiation Gene Induction and Apoptosis Inhibition by Interleukin-9. Journal of Biological Chemistry. 09 September 1999, Vol. 274, No.36, pages 25855-25861.	33-49



INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24424

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

C07H 21/04; C12Q 1/68; C12N 15/00; C12N 1/21; A61K 38/19; C07K 14/52, 16/24;

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

536/23.5; 424/85.1, 85.2; 435/6, 7.1, 69.1, 252.3, 320.1; 530/351, 388.2;

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24424

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-32  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
No CRF for this case has been filed. The instant claims recite SEQ ID NO:s or depend therefrom and cannot be searched other than by a sequence search.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.